
Investing in the Grail stock symbol can be a bit confusing, but don't worry, we've got you covered. The Grail stock symbol is listed on the NASDAQ stock exchange under the ticker symbol GRIL.
Understanding the Grail stock symbol requires a basic knowledge of the company's background. Grail is a biotechnology company that specializes in cancer detection and diagnosis.
The company's mission is to detect cancer early, when it's most treatable. Grail's technology uses next-generation sequencing to identify cancer biomarkers.
Grail's stock price has been steadily increasing over the past year, with a current market capitalization of over $10 billion.
Additional reading: Ticker Symbol S
For another approach, see: Newsmax Stock Symbol
Stock Overview
GRAL stock has a Snowflake Score of 0/6 for Valuation, indicating potential concerns about its price.
Revenue is forecast to grow 16.29% per year, which could be a significant driver of the stock's value.
Financial Health is rated 6/6, suggesting that the company has a strong financial foundation.
The company's Future Growth is scored 1/6, indicating potential concerns about its long-term growth prospects.
GRAL's Past Performance and Dividends are both scored 0/6, indicating that the company may not have a track record of delivering strong returns or paying dividends.
If this caught your attention, see: S B I Card Share Price
Financial Performance
GRAIL's share price has been on a rollercoaster ride, with a 52 Week High of US$63.99 and a 52 Week Low of US$12.33. The current share price is US$45.30.
The company's revenue has been increasing, with a 34.90% jump in 2024 to $125.60 million, compared to the previous year's $93.11 million. This growth is a promising sign for investors.
GRAIL's share price has seen significant changes in the past year, with a 1 Month Change of 58.34% and a 3 Month Change of 158.56%. This rapid growth might be a good opportunity for investors to consider.
Here's a quick summary of GRAIL's financial performance:
- 2024 Revenue: $125.60 million
- 2024 Revenue Growth: 34.90%
- 2024 Losses: -$2.03 billion
- Change since IPO: 231.63%
Financial Performance
GRAIL's current share price is $45.30, which is a significant increase from its 52 Week Low of $12.33.
The company's 52 Week High is $63.99, and its Beta is 0, indicating that its stock price is not closely tied to the overall market.
GRAIL's 1 Month Change is a staggering 58.34%, and its 3 Month Change is an even more impressive 158.56%.
For another approach, see: Change Healthcare Stock Symbol
However, the company's 1 Year Change is not available, and its 3 Year and 5 Year Changes are also not provided.
GRAIL's revenue in 2024 was $125.60 million, a 34.90% increase from the previous year's $93.11 million.
Unfortunately, the company's losses were substantial, totaling -$2.03 billion in 2024, which is 38.3% more than in 2023.
GRAIL's Change since IPO is a remarkable 231.63%, indicating a significant increase in the company's value since its initial public offering.
A fresh viewpoint: Shiller Pe Ratio 2024
Analyst Forecast
According to 2 analysts, the average rating for GRAL stock is "Hold".
The 12-month stock price forecast is $16.0, which is a significant decrease of -64.68% from the latest price.
Investor Insights
Grail's stock symbol, GRLI, has been a hot topic among investors, with many wondering if it's a good time to get in on the action.
Grail's focus on cancer diagnosis has the potential to disrupt the entire healthcare industry, with a market size of $1.2 trillion in the United States alone.
A unique perspective: Class S Shares
The company's innovative approach to detecting cancer early has shown promise in clinical trials, with a 97% accuracy rate in detecting cancer from a single blood sample.
Investors are taking a close look at Grail's financials, with a market capitalization of $15.6 billion and a revenue growth rate of 100% YoY.
The biotech industry is known for its high risks and high rewards, but Grail's unique technology and strong management team make it an attractive investment opportunity for some.
See what others are reading: The Dhandho Investor the Low-risk Value Method to High Returns
Valuation and Performance
GRAIL stock has seen significant changes in its share price over the past year, with a 58.34% increase in the last month alone.
The company's current share price is $45.30, a far cry from its 52-week low of $12.33. This is a notable turnaround, but it's essential to consider the bigger picture.
GRAIL's revenue has been increasing, with a 34.90% jump in 2024 compared to the previous year. However, the company still reported significant losses of $2.03 billion in 2024.
Here's a comparison of GRAIL's valuation metrics:
These metrics give us a glimpse into GRAIL's valuation, but it's crucial to analyze them in the context of the company's overall performance.
Price History & Performance
The share price of GRAIL has been on a wild ride. The current share price is a whopping $45.30.
One of the most notable things about GRAIL's price history is the massive 58.34% increase in the past month, which is a staggering figure. This growth is not a one-time fluke, as the company has seen a 158.56% increase in the past three months.
GRAIL's share price has been on a tear, with a 231.63% increase since its IPO. This is a testament to the company's growth and potential.
Here's a breakdown of GRAIL's price history:
Price Volatility
GRAL's price volatility is a concern, with an average weekly movement of 20.8%. This is significantly higher than the market average of 6.0%.
GRAL's volatility is also higher than the biotechs industry average of 10.9%. This suggests that GRAL's price is more susceptible to fluctuations.
In comparison, GRAL's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
Here's a comparison of GRAL's volatility with other stocks in the US market:
GRAL's share price has been volatile over the past 3 months, making it a riskier investment.
Valuation
Valuation is a crucial aspect of assessing a company's performance. It helps investors and analysts determine whether a company's stock price is justified based on its financials.
The price-to-earnings (P/E) ratio is a key valuation metric. For GRAL, the normalized P/E ratio is 26.91, indicating that investors are willing to pay $26.91 for every dollar of earnings.
In contrast, PSNL has a normalized P/E ratio that is not available, suggesting that its earnings are not as easily comparable. The P/E ratio can vary significantly between companies, and it's essential to consider this when evaluating a company's valuation.
A lower P/E ratio may indicate that a company's stock price is undervalued, while a higher ratio may suggest that it's overvalued. However, this is not always the case, and other factors like growth prospects and industry trends must be considered.
Here's a comparison of the price-to-book value (P/B) ratios for GRAL, 688468, and PSNL:
The price-to-sales (P/S) ratio can also provide insights into a company's valuation. For GRAL, the P/S ratio is 11.51, indicating that investors are willing to pay $11.51 for every dollar of sales. In contrast, PSNL's P/S ratio is 2.79, suggesting that its stock price is relatively lower compared to its sales.
Worth a look: S&p 500 P/e Ratio Current
A lower P/S ratio may indicate that a company's stock price is undervalued, while a higher ratio may suggest that it's overvalued. However, this is not always the case, and other factors like growth prospects and industry trends must be considered.
The price-to-cash flow (P/CF) ratio can also be a useful metric for evaluating a company's valuation. For 688468, the P/CF ratio is 17.66, indicating that investors are willing to pay $17.66 for every dollar of cash flow.
Related reading: Bhp Billiton Stock Quote
Featured Images: pexels.com


